2022, Articolo in rivista, ENG
Lacorte E; Piscopo P; Sagliocca L; Vignatelli L; Taruscio D; Vanacore N; Bacigalupo I; Beccani L; Bellomo G; Bertini E; Biagiotti S; Borgatti R; Bramati A; Cammarano R; Ceccarini A; Corti C; Della Gatta F; Della Seta M; Faccioli S; Gainotti S; Gaudiano A; Gervasi G; Ginevrino M; Mariotti C; Mayer F; Mennini FS; Micalizzi A; Nuovo S; Pandarese D; Parisi P; Penna L; Petrarca M; Pioggia G; Raucci U; Romaniello R; Sacchi D; Salvaggiulo V; Sciattella P; Schirinzi T; Tofani M; Torreri P; Valente EM; Vasco G; Zaccaria V; Zanni G.
Background: Ataxia is a rare neurological condition causing a deficit in the coordination of motor activities, preventing the fluidity of movements. Children with ataxia may show several different ataxic signs, along with difficulties in walking autonomously and ataxic gait often associated with trunk instability. Ataxic signs can be either acute or chronic, and in either case, the diagnosis can be extremely complex. Symptoms and their etiology are often widely heterogeneous, even within the same condition. Methods: The guideline was developed based on the methodology defined by the Methodological Handbook of the Italian National Guideline System (SNLG) and was reported following the AGREE-II checklist. The SNLG methodology required the adoption of the GRADE approach for the whole development process. To facilitate the implementation of the contents and recommendations from the guideline, two care pathways were developed based on the NICE and the European Pathway Association (EPA) models. Results: The guideline included 28 clinical questions, 4 on the identification and management of acute ataxias, and 24 on the diagnosis and management of chronic ataxias. The document included 44 recommendations, 37 clinical recommendations, and 7 recommendations for research. Conclusion: The working group, despite the lack and methodological limitations of the evidence, deemed as essential to provide indications and recommendations, in particular in some clinically relevant areas. The care pathway was produced as a tool to facilitate the implementation of the contents and recommendations. The interactive version of the pathway is available on the SNLG website along with a leaflet dedicated to families and caregivers.
2022, Articolo in rivista, ENG
Stanganelli, Ignazio; Spagnolo, Francesco; Argenziano, Giuseppe; Ascierto, Paolo A.; Bassetto, Franco; Bossi, Paolo; Donato, Vittorio; Massi, Daniela; Massone, Cesare; Patuzzo, Roberto; Pellacani, Giovanni; Quaglino, Pietro; Queirolo, Paola; Zalaudek, Iris; Palmieri, Giuseppe; Italian MelanomaIntergrp IMI
Simple Summary Cutaneous squamous cell carcinoma is one of the most common forms of cancer. Although most cases are cured with surgical excision, a few tumors are associated with a high risk of local or distant relapse; therefore, it is relevant to identify high-risk lesions among all other low-risk CSCCs for the proper diagnostic and therapeutic management. Chemotherapy achieves mostly short-lived responses that do not lead to a curative effect and are associated with severe toxicities. Recently, PD-1 inhibitor cemiplimab was approved by the regulatory authorities for the treatment of advanced cutaneous squamous cell carcinoma; subsequently, the anti-PD-1 agent pembrolizumab received the approval by the FDA only in the same setting. Here, we provide a literature review and clinical recommendations by a panel of experts regarding the diagnosis, treatment, and follow-up of cutaneous squamous cell carcinoma. Cutaneous squamous cell carcinomas (CSCC) account for about 20% of all keratinocyte carcinomas, which are the most common form of cancer. Heterogeneity of treatments and low mortality are a challenge in obtaining accurate incidence data and consistent registration in cancer registries. Indeed, CSCC mostly presents as an indolent, low-risk lesion, with five-year cure rates greater than 90% after surgical excision, and only few tumors are associated with a high-risk of local or distant relapse; therefore, it is particularly relevant to identify high-risk lesions among all other low-risk CSCCs for the proper diagnostic and therapeutic management. Chemotherapy achieves mostly short-lived responses that do not lead to a curative effect and are associated with severe toxicities. Due to an etiopathogenesis largely relying on chronic UV radiation exposure, CSCC is among the tumors with the highest rate of somatic mutations, which are associated with increased response rates to immunotherapy. Thanks to such strong pre-clinical rationale, clinical trials led to the approval of anti-PD-1 cemiplimab by the FDA (Food and Drug Administration) and EMA (European Medicines Agency), and anti-PD-1 pembrolizumab by the FDA only. Here, we provide a literature review and clinical recommendations by a panel of experts regarding the diagnosis, treatment, and follow-up of CSCC.
2018, Rapporto di ricerca (Research report), FRE
Hicks D., Baroni P., Ceberio Berger K., Gurrutxaga Hernaiz A., Kruse E., Quochi V., Russo I., Salonen T., Sarhimaa A., Soria C.
Le raccomandazioni del progetto DLDP rivolte ai decisori politici (versione francese sintetica)
2018, Rapporto di ricerca (Research report), GER
Hicks D., Baroni P., Ceberio Berger K., Gurrutxaga Hernaiz A., Kruse E., Quochi V., Russo I., Salonen T., Sarhimaa A., Soria C.
Le raccomandazioni del progetto DLDP rivolte ai decisori politici (versione tedesca sintetica)
2018, Rapporto di ricerca (Research report), FIU
Salonen T., Baroni P., Ceberio Berger K., Gurrutxaga Hernaiz A., Hicks D., Kruse E., Quochi V., Russo I., Sarhimaa A., Soria C.
Le raccomandazioni del progetto DLDP per migliorare la vitalità digitale della lingua careliana (versione careliana)
2018, Rapporto di ricerca (Research report), ITA
Baroni P., Quochi V., Russo I., Soria C., Ceberio Berger K., Gurrutxaga Hernaiz A., Hicks D., Kruse E., Salonen T., Sarhimaa A.
Le raccomandazioni del progetto DLDP per migliorare la vitalità digitale della lingua sarda (versione italiana)
2018, Rapporto di ricerca (Research report), BAQ
Hicks D., Baroni P., Ceberio Berger K., Gurrutxaga Hernaiz A., Kruse E., Quochi V., Russo I., Salonen T., Sarhimaa A., Soria C.
Le raccomandazioni del progetto DLDP rivolte ai decisori politici (versione basca sintetica)
2018, Rapporto di ricerca (Research report), ITA
Hicks D., Baroni P., Ceberio Berger K., Gurrutxaga Hernaiz A., Kruse E., Quochi V., Russo I., Salonen T., Sarhimaa A., Soria C.
Le raccomandazioni del progetto DLDP rivolte ai decisori politici (versione italiana sintetica)
2018, Rapporto di ricerca (Research report), SPA
Hicks D., Baroni P., Ceberio Berger K., Gurrutxaga Hernaiz A., Kruse E., Quochi V., Russo I., Salonen T., Sarhimaa A., Soria C.
Le raccomandazioni del progetto DLDP rivolte ai decisori politici (versione spagnola sintetica)
2018, Rapporto di ricerca (Research report), FIN
Hicks D., Baroni P., Ceberio Berger K., Gurrutxaga Hernaiz A., Kruse E., Quochi V., Russo I., Salonen T., Sarhimaa A., Soria C.
Le raccomandazioni del progetto DLDP rivolte ai decisori politici (versione finlandese sintetica)
2018, Rapporto di ricerca (Research report), ENG
Hicks D., Baroni P., Ceberio Berger K., Gurrutxaga Hernaiz A., Kruse E., Quochi V., Russo I., Salonen T., Sarhimaa A., Soria C.
Le raccomandazioni del progetto DLDP rivolte ai decisori politici (versione inglese sintetica)
2018, Rapporto di ricerca (Research report), FIN
Salonen T., Baroni P., Ceberio Berger K., Gurrutxaga Hernaiz A., Hicks D., Kruse E., Quochi V., Russo I., Sarhimaa A., Soria C.
Le raccomandazioni del progetto DLDP per la sopravvivenza digitale della lingua careliana (versione finlandese)
2018, Rapporto di ricerca (Research report), FRE
Hicks D., Soria C., Baroni P., Ceberio Berger K., Gurrutxaga Hernaiz A., Kruse E., Quochi V., Russo I., Salonen T., Sarhimaa A.
Le raccomandazioni del progetto DLDP per la sopravvivenza digitale del bretone (versione francese)
2018, Rapporto di ricerca (Research report), BRE
Hicks D., Soria C., Baroni P., Ceberio Berger K., Gurrutxaga Hernaiz A., Kruse E., Quochi V., Russo I., Salonen T., Sarhimaa A.
Le raccomandazioni del progetto DLDP per la sopravvivenza digitale del bretone (versione bretone)
2018, Rapporto di ricerca (Research report), SPA
Ceberio Berger K., Gurrutxaga Hernaiz A., Baroni P., Hicks D.,Kruse E., Quochi V., Russo I., Salonen T., Sarhimaa A., Soria C.
Le raccomandazioni del progetto DLDP per la sopravvivenza digitale del basco (versione spagnola)
2018, Rapporto di ricerca (Research report), BAQ
Ceberio Berger K., Gurrutxaga Hernaiz A., Baroni P., Hicks D.,Kruse E., Quochi V., Russo I., Salonen T., Sarhimaa A., Soria C.
Le raccomandazioni del progetto DLDP per la sopravvivenza digitale della lingua basca (versione basca)
2018, Rapporto di ricerca (Research report), ENG
Hicks D., Baroni P., Ceberio Berger K., Gurrutxaga Hernaiz A., Kruse E., Quochi V., Russo I., Salonen T., Sarhimaa A., Soria C.
Le raccomandazioni del progetto DLDP rivolte ai decisori politici (versione inglese integrale)
2017, Articolo in rivista, ENG
Galli, M.; Antinori, S.; Atzeni, F.; Meroni, L.; Riva, A.; Scire, C.; Adorni, F.; Quartuccio, L.; Sebastiani, M.; Airo, P.; Bazzichi, L.; Cristini, F.; Del Bono, V.; Manfredi, A.; Viapiana, O.; De Rosa, F.; Favalli, E.; Petrelli, E.; Salvarani, C.; Govoni, M.; Corcione, S.; Scrivo, R.; Sarmati, L.; Lazzarin, A.; Grassi, W.; Mastroianni, C.; Gaeta, G. B.; Ferraccioli, G.; Cutolo, M.; De Vita, S.; Lapadula, G.; Matucci-Cerinic, M.; Armignacco, O.; Sarzi-Puttini, P.
Often life-threatening pulmonary fungal infections (PFIs) can occur in patients with rheumatoid arthritis (RA) receiving disease-modifying anti-rheumatic drugs (DMARDs). Most of the data concerning PFIs in RA patients come from case reports and retrospective case series. Of the five most widely described PFIs, Pneumocystis jirovecii pneumonia (PJP) has rarely been seen outside Japan, pulmonary cryptococcosis has been diagnosed in only a small number of patients worldwide, pulmonary coccidioidomycosis has almost only been observed in endemic areas, the limited number of cases of pulmonary histoplasmosis have mainly occurred in the USA, and the rare cases of invasive pulmonary aspergillosis have only been encountered in leukopenic patients. Many aspects of the prophylaxis, diagnosis and treatment of PFIs in RA patients remain to be defined, as does the role of each DMARD in increasing the risk of infection, and the possibility of resuming biological and non-biological DMARD treatment after the infection has been cured. The recommendations for the management of PFIs described in this paper are the product of a consensus procedure promoted by the Italian group for the Study and Management of Infections in Patients with Rheumatic Diseases (the ISMIR group).
2004, Articolo in rivista, ENG
Rotilio G; Berni Canani R; Barba G; Branca F; Cairella G; Dilaghi B; Fieschi C; Garbagnati F; Gentile MG; Gensini GF; Gualtieri A; Inzitari D; La Massa M; Luisi ML; Mancia G; Marcelli M; Masini ML; Mastrilli F; Paolucci S; Pratesi L; Rubba P; Sacchetti ML; Salvia A; Scalfi L; Scognamiglio U; Siani A; Strazzullo P; Italian Working Group on Nutrition and Stroke Prevention.